Different means to the same end

Seton-Rogers, Sarah

doi:10.1038/nrc3886

In Brief
Published: 23 December 2014

Resistance

Different means to the same end

Sarah Seton-Rogers

Nature Reviews Cancer volume 15, page 2 (2015)Cite this article

996 Accesses
Metrics details

Subjects

Access through your institution

Buy or subscribe

Juric and Castel et al. examined the development of resistance to the PI3K p110α inhibitor BYL719 in a patient with metastatic breast cancer who had responded initially, but later relapsed and died. The authors collected samples from 14 metastatic sites during rapid autopsy and found that all lesions had loss of one copy of PTEN, and those that had developed resistance to BYL719 treatment had heterogeneous genetic alterations that resulted in the complete loss of PTEN expression. This suggests that parallel evolution occurs at metastatic sites, leading to the same phenotypic outcome in all of them.

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

Purchase on SpringerLink
Instant access to full article PDF

Buy now

Prices may be subject to local taxes which are calculated during checkout

References

Juric, D. & Castel, P. et al. Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor. Nature http://dx.doi.org/10.1038/nature13948 (2014)

Download references

Authors